Briumvi’s New Subcutaneous Formulation Boosts TG Therapeutics Stock
TG Therapeutics stock rose after early trial results showed its under-skin MS drug worked well and may allow at-home dosing.
/ 352 items
#XY Event-Driven Stocks↓
Wall Street Upgrades Rezolute After Strong Phase 3 Trial Results in Tumor Hyperinsulinism
Rezolute’s drug showed strong Phase 3 results, reducing IV glucose needs in rare tumor HI. Analysts raised targets and turned bullish.
Medline Shares Tumble After FDA Slams Repeated Bacteria Contamination at Illinois Plant
FDA warned Medline over contamination issues at Illinois plant. Stock fell. Company must fix cleaning and safety problems quickly.
Celcuity’s Breast Cancer Drug Outperforms Rivals at ASCO, Yet Wall Street Still Reacts Negatively
Celcuity’s gedatolisib doubled progression-free survival (11.1 vs 5.6 months) compared with Novartis’ Piqray in a Phase 3 breast cancer trial presented at ASCO 2026, but fell short of high market expectations.
FDA Delays Cingulate’s ADHD Drug Approval – But No Safety or Efficacy Issues
FDA asked Cingulate to fix manufacturing details for ADHD drug; no safety issues. Company will update and resubmit soon.
Cancer Cases Cloud Abivax’s Landmark Phase 3 Win in Ulcerative Colitis
Abivax ulcerative colitis drug showed strong results, but cancer cases raised safety worries, sending shares down sharply.